Deucravacitinib: moderate-to-severe plaque psoriasis preventable?
-
Manmeet Kaur
Abstract
Psoriasis is a persistent, inflammatory, and autoimmune condition that is difficult to treat. Estimates of the prevalence of psoriasis in people range from 0.27 % (95 % confidence interval 0.17 to 0.36) to 11.4 %, depending on factors such as age, sex, geography, ethnicity, genetics, and environmental factors. While systemic treatments are typically required for patients with moderate-to-severe instances of psoriasis, topical therapies are frequently effective for treating minor forms. In fact, phototherapy is frequently constrained by logistical considerations, and conventional systemic therapies are frequently avoided due to contraindications or the danger of adverse outcomes. In order to better serve the patient and achieve a greater level of quality of life, especially in order to sustain long-term efficacy, there is still a need for innovative therapies, which are always welcomed. Deucravacitinib is a first-in-class oral tyrosine kinase 2 (TYK2) inhibitor that is extremely selective. Through an allosteric mechanism, it stabilises an inhibitory connection between the regulatory and catalytic domains of TYK2’s pseudokinase regulatory domain, which is catalytically inactive. This can be used to treat a variety of immune-mediated conditions, such as inflammatory bowel disease, lupus, psoriatic arthritis, and psoriasis. US-FDA has approved this drug on 9 September 2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. This article aims to review the current knowledge on the efficacy and safety of deucravacitinib for the management of psoriasis.
-
Research ethics: This study was conducted according to the guidelines laid down in the Declaration of Helsinki.
-
Informed consent: Not required.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Yes, all authors state that there is no conflict of interest.
-
Research funding: None.
-
Data availability: Not applicable.
References
1. Lé, AM, Puig, L, Torres, T. Deucravacitinib for the treatment of psoriatic disease. Am J Clin Dermatol 2022;23:813–22. https://doi.org/10.1007/s40257-022-00720-0.Search in Google Scholar PubMed PubMed Central
2. Armstrong, AW, Read, C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA, J Am Med Assoc 2020;323:1945–60. https://doi.org/10.1001/jama.2020.4006.Search in Google Scholar PubMed
3. Gerdes, S, Körber, A, Biermann, M, Karnthaler, C, Reinhardt, M. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. J Dermatol Treat 2020;31:470–5. https://doi.org/10.1080/09546634.2020.1746734.Search in Google Scholar PubMed
4. Armstrong, AW, Schupp, C, Wu, J, Bebo, B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation Survey Data 2003–2011. PLoS One 2012;7:e52935. https://doi.org/10.1371/journal.pone.0052935.Search in Google Scholar PubMed PubMed Central
5. Hawkes, JE, Yan, BY, Chan, TC, Krueger, JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol 2018;201:1605–13. https://doi.org/10.4049/jimmunol.1800013.Search in Google Scholar PubMed PubMed Central
6. Girolomoni, G, Strohal, R, Puig, L, Bachelez, H, Barker, J, Boehncke, WH, et al.. The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol 2017;31:1616–26. https://doi.org/10.1111/jdv.14433.Search in Google Scholar PubMed PubMed Central
7. Hawkes, JE, Chan, TC, Krueger, JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol 2017;140:645–53. https://doi.org/10.1016/j.jaci.2017.07.004.Search in Google Scholar PubMed PubMed Central
8. Bergboer, J, Zeeuwen, P, Schalkwijk, J. Genetics of psoriasis: evidence for epistatic interaction between skin barrier abnormalities and immune deviation. J Invest Dermatol 2012;132:2320–31. https://doi.org/10.1038/jid.2012.167.Search in Google Scholar PubMed
9. Alwan, W, Nestle, FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol 2015;33(5 Suppl 93):S2–6. [Epub 2015 Oct 15].Search in Google Scholar
10. Yamanaka, K, Yamamoto, O, Honda, T. Pathophysiology of psoriasis: a review. J Dermatol 2021;48:722–31. https://doi.org/10.1111/1346-8138.15913.Search in Google Scholar PubMed
11. Roskoski, RJr. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis. Pharmacol Res 2023;189:106642. https://doi.org/10.1016/j.phrs.2022.106642.Search in Google Scholar PubMed
12. Parisi, R, Symmons, DP, Griffiths, CE, Ashcroft, DM, Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133:377–85. https://doi.org/10.1038/jid.2012.339.Search in Google Scholar PubMed
13. Takeshita, J, Grewal, S, Langan, SM, Mehta, NN, Ogdie, A, Van Voorhees, AS, et al.. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 2017;76:377–90. https://doi.org/10.1016/j.jaad.2016.07.064.Search in Google Scholar PubMed PubMed Central
14. Amin, M, Lee, EB, Tsai, TF, Wu, JJ. Psoriasis and Co-morbidity. Acta Derm Venereol 2020;100:adv00033. https://doi.org/10.2340/00015555-3387.Search in Google Scholar PubMed PubMed Central
15. Boehncke, WH, Schon, MP. Psoriasis. Lancet 2015;386:983–94. https://doi.org/10.1016/s0140-6736(14)61909-7.Search in Google Scholar
16. Rendon, A, Schakel, K. Psoriasis pathogenesis and treatment. Int J Mol Sci 2019;20:1475. https://doi.org/10.3390/ijms20061475.Search in Google Scholar PubMed PubMed Central
17. Balak, DMW, Gerdes, S, Parodi, A, Salgado-Boquete, L. Long-term safety of oral systemic therapies for psoriasis: a comprehensive review of the literature. Dermatol Ther 2020;10:589–613. https://doi.org/10.1007/s13555-020-00409-4.Search in Google Scholar PubMed PubMed Central
18. Balogh, EA, Bashyam, AM, Ghamrawi, RI, Feldman, SR. Emerging systemic drugs in the treatment of plaque psoriasis. Expet Opin Emerg Drugs 2020;25:89–100. https://doi.org/10.1080/14728214.2020.1745773.Search in Google Scholar PubMed
19. Kamata, M, Tada, Y. Safety of biologics in psoriasis. J Dermatol 2018;45:279–86. https://doi.org/10.1111/1346-8138.14096.Search in Google Scholar PubMed
20. Kalb, RE, Fiorentino, DF, Lebwohl, MG, Toole, J, Poulin, Y, Cohen, AD, et al.. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol 2015;151:961–9. https://doi.org/10.1001/jamadermatol.2015.0718.Search in Google Scholar PubMed
21. Clark, JD, Flanagan, ME, Telliez, JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 2014;57:5023–38. https://doi.org/10.1021/jm401490p.Search in Google Scholar PubMed
22. Banerjee, S, Biehl, A, Gadina, M, Hasni, S, Schwartz, DM. JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs 2017;77:521–46. https://doi.org/10.1007/s40265-017-0701-9.Search in Google Scholar PubMed PubMed Central
23. Catlett, IM, Hu, Y, Gao, L, Banerjee, S, Gordon, K, Krueger, JG. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol 2021. https://doi.org/10.1016/j.jaci.2021.11.001.Search in Google Scholar PubMed
24. Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, Strange, A, Capon, F, Spencer, CC, Knight, J, Weale, ME, Allen, MH, et al.. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010;42:985–90. https://doi.org/10.1038/ng.694.Search in Google Scholar PubMed PubMed Central
25. Ghoreschi, K, Laurence, A, O’Shea, JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228:273–87. https://doi.org/10.1111/j.1600-065x.2008.00754.x.Search in Google Scholar
26. Hoy, SM. Deucravacitinib: first approval. Drugs 2022;82:1671–9. https://doi.org/10.1007/s40265-022-01796-y.Search in Google Scholar PubMed PubMed Central
27. Catlett, IM, Aras, U, Hansen, L, Liu, Y, Bei, D, Girgis, IG, et al.. First-in-human study of deucravacitinib: a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2. Clin Transl Sci 2023;16:151–64. https://doi.org/10.1111/cts.13435.Search in Google Scholar PubMed PubMed Central
28. Chimalakonda, A, Burke, J, Cheng, L, Catlett, I, Tagen, M, Zhao, Q, et al.. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1/2/3 inhibitors. Dermatol Ther 2021;11:1763–76. https://doi.org/10.1007/s13555-021-00596-8.Search in Google Scholar PubMed PubMed Central
29. Wrobleski, ST, Moslin, R, Lin, S, Zhang, Y, Spergel, S, Kempson, J, et al.. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem 2019;62:8973–95. https://doi.org/10.1021/acs.jmedchem.9b00444.Search in Google Scholar PubMed
30. Bristol Myers Squibb. Home page in Internet] SOTYKTU™ (deucravacitinib) tablets, for oral use: US prescribing information; 2022. [Last cited on 04th June 2023] Available from: https://packageinserts.bms.com/pi/pi_sotyktu.pdf [Accessed 12 Sep 2022].Search in Google Scholar
31. Food and drug administration (FDA) [home page in Internet] Approved Drug Products: SOTYKTU (deucravacitinib) tablets, for oral use. [Last cited on 4th June 2023] Available from: https://packageinserts.bms.com/pi/pi_sotyktu.pdf.Search in Google Scholar
32. Drugbank [Home page in Internet] Deurcratinib mechanism of action. [Last cited on 4th June 2023]. Available from: https://go.drugbank.com/drugs/DB16650.Search in Google Scholar
33. Chimalakonda, A, Singhal, S, Darbenzio, R, Dockens, R, Marchisin, D, Banerjee, S, et al.. Lack of electrocardiographic effects of deucravacitinib in healthy subjects. Clin Pharmacol Drug Dev 2022;11:442–53. https://doi.org/10.1002/cpdd.1056.Search in Google Scholar PubMed PubMed Central
34. Mease, PJ, Deodhar, AA, van der Heijde, D, Behrens, F, Kivitz, AJ, Neal, J, et al.. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis 2022;81:815–22. https://doi.org/10.1136/annrheumdis-2021-221664.Search in Google Scholar PubMed PubMed Central
35. Papp, K, Gordon, K, Thaçi, D, Morita, A, Gooderham, M, Foley, P, et al.. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med 2018;379:1313–21. https://doi.org/10.1056/nejmoa1806382.Search in Google Scholar
36. Thaçi, D, Strober, B, Gordon, KB, Foley, P, Gooderham, M, Morita, A, et al.. Deucravacitinib in moderate to severe psoriasis: clinical and quality-of-life outcomes in a phase 2 trial. Dermatol Ther 2022;12:495–510. https://doi.org/10.1007/s13555-021-00649-y.Search in Google Scholar PubMed PubMed Central
37. Imafuku, S, Tada, Y, Hippeli, L, Banerjee, S, Morita, A, Ohtsuki, M. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial. J Dermatol 2023;50:588–95. https://doi.org/10.1111/1346-8138.16740.Search in Google Scholar PubMed
38. Strober, B, Thaçi, D, Sofen, H, Kircik, L, Gordon, KB, Foley, P, et al.. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol 2023;88:40–51. https://doi.org/10.1016/j.jaad.2022.08.061.Search in Google Scholar PubMed
39. Armstrong, AW, Gooderham, M, Warren, RB, Papp, KA, Strober, B, Thaçi, D, et al.. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol 2023;88:29–39. https://doi.org/10.1016/j.jaad.2022.07.002.Search in Google Scholar PubMed
40. Zhang, L, Guo, L, Wang, L, Jiang, X. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis – a network meta-analysis. J Eur Acad Dermatol Venereol 2022;36:1937–46. https://doi.org/10.1111/jdv.18263.Search in Google Scholar PubMed
© 2024 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Editorials
- Targeting Rho GTPase regulators in cancer: are we hitting the mark?
- The pitfalls of linear regression in physiological research
- Reviews
- Lipid profile and mortality in patients with pulmonary thromboembolism; a systematic review and meta-analysis
- IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective
- Deucravacitinib: moderate-to-severe plaque psoriasis preventable?
- The key roles of thyroid hormone in mitochondrial regulation, at interface of human health and disease
- Uncovering the coronavirus outbreak: present understanding and future research paths
- Effects of thyroid hormones in skeletal muscle protein turnover
- Original Articles
- Effect of high-intensity interval training vs. moderate-intensity continuous training on cardiometabolic risk factors in overweight and obese individuals
- Alcohol promotes liver fibrosis in high fat diet induced diabetic rats
- Association between aerobic performance and physiological responses in Yo-Yo intermittent recovery test level 2, and the futsal-specific intermittent endurance test in trained futsal players
- Oral vs. injected: which vitamin D boost works best for low levels?
- Effects of an 8-week intervention of anulom vilom pranayama combined with heartfulness meditation on psychological stress, autonomic function, inflammatory biomarkers, and oxidative stress in healthcare workers during COVID-19 pandemic: a randomized controlled trial
- Ureteral access sheaths in RIRS: a retrospective, comparative, single-center study
Articles in the same Issue
- Frontmatter
- Editorials
- Targeting Rho GTPase regulators in cancer: are we hitting the mark?
- The pitfalls of linear regression in physiological research
- Reviews
- Lipid profile and mortality in patients with pulmonary thromboembolism; a systematic review and meta-analysis
- IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective
- Deucravacitinib: moderate-to-severe plaque psoriasis preventable?
- The key roles of thyroid hormone in mitochondrial regulation, at interface of human health and disease
- Uncovering the coronavirus outbreak: present understanding and future research paths
- Effects of thyroid hormones in skeletal muscle protein turnover
- Original Articles
- Effect of high-intensity interval training vs. moderate-intensity continuous training on cardiometabolic risk factors in overweight and obese individuals
- Alcohol promotes liver fibrosis in high fat diet induced diabetic rats
- Association between aerobic performance and physiological responses in Yo-Yo intermittent recovery test level 2, and the futsal-specific intermittent endurance test in trained futsal players
- Oral vs. injected: which vitamin D boost works best for low levels?
- Effects of an 8-week intervention of anulom vilom pranayama combined with heartfulness meditation on psychological stress, autonomic function, inflammatory biomarkers, and oxidative stress in healthcare workers during COVID-19 pandemic: a randomized controlled trial
- Ureteral access sheaths in RIRS: a retrospective, comparative, single-center study
